生物标志物在药物性肝损伤中应用的研究进展

Advances in the Application of Biomarkers in Drug-induced Liver Injury

药物性肝损伤是伴随着药物使用而出现的最常见不良反应之一,也是药物研发失败及药物撤市或限制使用的主要原因。生物标志物检测是临床前药物肝毒性评价和临床患者潜在肝损伤诊断的重要技术手段,而传统的肝损伤指标因缺乏特异性和灵敏性等因素,限制了其在早期评价中的应用。因此,寻求及验证新的生物标志物势在必行。本文主要对结合现代组学等技术探索出具有科研及临床价值的新型生物标志物研究现状予以概述。以期为科研人员、临床医师、新药研发机构等预测药物的肝毒性及可能的发展趋势,判断药物引起的肝损伤程度等提供参考。

Drug-induced liver injury is one the cause of serious reactions during drug use and the main drug attrition during drug development and post-marketing drug withdrawal.Biomarkers are important tools for evaluating preclinical drug hepatotocixity and clinical diagnosis of potential liver injury in patients.Due to the sensitivity,specificity and other factors,traditional indicators have limitations in the application of early evaluation.So discovery and verification of new biomarkers have imperatived.This paper summarizes the newly discovery liver injury biomarkers with scientific and clinical value from the new platform of modern science and technology.In order to better forecast hepatotoxicity of drugs,development trend,diagnosis the degree of liver damage,which could provide references for researchers,clinicians,new drug research and development institutions.